{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002089","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.725405+00:00","generated_at":"2026-06-17T07:02:15.314122+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Corvus Pharma reduces CEO salary from $300K to $34,840; grants 800K options","bullets":["CEO base salary cut to $34,840/year effective March 31, 2023, from $300,000.","Option to purchase 800,000 shares granted, vesting monthly over 36 months.","Compensation Committee approved the changes on March 29, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002089","json":"https://secwatch.observer/filing/0001171843-23-002089.json","markdown":"https://secwatch.observer/filing/0001171843-23-002089.md","text":"https://secwatch.observer/filing/0001171843-23-002089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323002089/0001171843-23-002089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323002089/f8k_040323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:02:15.314122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}